PMID- 28469959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 7
IP  - 4
DP  - 2017
TI  - Treatment with the C-C chemokine receptor type 5 (CCR5)-inhibitor maraviroc 
      suppresses growth and induces apoptosis of acute lymphoblastic leukemia cells.
PG  - 869-880
AB  - Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy 
      diagnosed in children and is a malignant disorder that originates from one single 
      hematopoietic precursor committed to B- or T-cell lineage. C-C chemokine receptor 
      type 5 (CCR5) is a chemokine and chemokine receptor pair playing critical roles 
      in tumorigenesis. A highly potent competitive antagonist of CCR5, maraviroc, 
      recently has been identified with suppression of cancer cells aggressive in a 
      variety of cancers. However, the effects of maraviroc on ALL cells have not yet 
      been defined. Here we report that CCR5 selective inhibitor significantly 
      inhibited ALL cells SUP-B15 growth and induced SUP-B15 cells to undergo cell 
      apoptosis. This cell apoptosis was associated with increased levels of cleavage 
      of caspase-3 and caspase-9, and Poly (ADP-ribose) polymerase (PARP). Moreover, we 
      demonstrated that maraviroc strongly inhibited SUP-B15 cells migration to C-X-C 
      motif chemokine ligand 12 (CXCL12) and CXCL13, and adhesion to fibronectin and 
      vascular cell adhesion molecule 1 (VCAM-1) in vitro. Importantly, CCR5-activated 
      signaling proteins Janus Kinase 1 (JAK1), JAK2 and signal transducer and 
      activator of transcription (STAT3) were inhibited by maraviroc. Finally, 
      maraviroc suppressed the growth of SUP-B15 xenograft tumors in athymic mice. 
      Collectively, this study demonstrated that CCR5 inhibition by maraviroc has the 
      potential for the treatment of human ALL.
FAU - Zi, Jie
AU  - Zi J
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Yuan, Shushu
AU  - Yuan S
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
FAU - Qiao, Jianlin
AU  - Qiao J
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Zhao, Kai
AU  - Zhao K
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Xu, Linyan
AU  - Xu L
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Qi, Kunming
AU  - Qi K
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Xu, Kailin
AU  - Xu K
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
FAU - Zeng, Lingyu
AU  - Zeng L
AD  - Blood Diseases Institute, Xuzhou Medical UniversityNo. 99, West Huaihai Road, 
      Xuzhou, Jiangsu Province, China.
AD  - Key Laboratory of Bone Marrow Stem CellNo. 99, West Huaihai Road, Xuzhou, Jiangsu 
      Province, China.
AD  - Department of Hematology, The Affiliated Hospital of Xuzhou Medical UniversityNo. 
      99, West Huaihai Road, Xuzhou, Jiangsu Province, China.
LA  - eng
PT  - Journal Article
DEP - 20170401
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC5411794
OTO - NOTNLM
OT  - ALL
OT  - CCR5
OT  - JAK
OT  - STAT3
OT  - maraviroc
COIS- None.
EDAT- 2017/05/05 06:00
MHDA- 2017/05/05 06:01
PMCR- 2017/04/01
CRDT- 2017/05/05 06:00
PHST- 2017/02/08 00:00 [received]
PHST- 2017/03/15 00:00 [accepted]
PHST- 2017/05/05 06:00 [entrez]
PHST- 2017/05/05 06:00 [pubmed]
PHST- 2017/05/05 06:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2017 Apr 1;7(4):869-880. eCollection 2017.